Literature DB >> 16216944

Interleukin 4 and interleukin 10 levels are elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Katharina Stoeck1, Monika Bodemer, Barbara Ciesielczyk, Bettina Meissner, Mario Bartl, Uta Heinemann, Inga Zerr.   

Abstract

BACKGROUND: In neurodegenerative diseases, increasing attention has been focused on inflammatory mediators such as pro-inflammatory and anti-inflammatory cytokines and their potential influence in the process of neurodegeneration. In prion diseases, much data has been gained on the cell culture and animal disease models level, but only limited information is available on humans affected by Creutzfeldt-Jakob disease (CJD).
OBJECTIVE: To obtain data on anti-inflammatory cytokines interleukin 4 and interleukin 10 in the cerebrospinal fluid of patients with CJD, patients with other dementia, and nondemented neurological patients and controls.
DESIGN: Cerebrospinal fluid samples were collected from CJD patients and control subjects, and concentrations of the anti-inflammatory cytokines interleukin 4 and interleukin 10 were determined using an enzyme-linked immunosorbent assay. PATIENTS: Cerebrospinal fluid samples from 61 patients were analyzed. The group was composed of patients with CJD (n = 20), patients with other forms of dementia (n = 10), patients with motoneuron disease (n = 6), patients with normal pressure hydrocephalus (n = 5), and control subjects (n = 20).
RESULTS: Interleukin 10 levels were significantly elevated in the cerebrospinal fluid of CJD patients (median, 9.8 pg/mL). The elevation was significant to other dementia (median, 7.9 pg/mL, P<.05), motoneuron disease (median, 7.9 pg/mL, P<.05), normal pressure hydrocephalus (median, 7.0 pg/mL, P<.05), and controls (median, 1.3 pg/mL, P<.001). Levels of interleukin 4 were significantly elevated in cerebrospinal fluid of patients with CJD (median, 26.4 pg/mL) compared with control subjects (median, 6.2 pg/mL, P<.001) and patients with a motoneuron disease (median, 10.5 pg/mL, P<.001)
CONCLUSIONS: Elevated levels of the anti-inflammatory cytokines interleukin 4 and interleukin 10 in cerebrospinal fluid of patients with CJD are new findings. The data of the present study provide a clue toward the possible role of cytokines as immunological modifiers in the neurodegenerative process of CJD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216944     DOI: 10.1001/archneur.62.10.1591

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  20 in total

1.  Detection of anti-glutamate receptor ε2 and anti-N-methyl-D: -aspartate receptor antibodies in a patient with sporadic Creutzfeldt-Jakob disease.

Authors:  Koji Fujita; Tatsuhiko Yuasa; Yukitoshi Takahashi; Keiko Tanaka; Shuji Hashiguchi; Katsuhito Adachi; Yuishin Izumi; Ryuji Kaji
Journal:  J Neurol       Date:  2011-11-05       Impact factor: 4.849

2.  Microbial exposures in infancy predict levels of the immunoregulatory cytokine interleukin-4 in Filipino young adults.

Authors:  Paula Skye Tallman; Christopher Kuzawa; Linda Adair; Judith B Borja; Thomas W McDade
Journal:  Am J Hum Biol       Date:  2012-02-05       Impact factor: 1.937

Review 3.  Microglia in prion diseases.

Authors:  Adriano Aguzzi; Caihong Zhu
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

4.  First symptom and initial diagnosis in sporadic CJD patients in Germany.

Authors:  Anna Krasnianski; Judith Kaune; Klaus Jung; Hans A Kretzschmar; Inga Zerr
Journal:  J Neurol       Date:  2014-07-15       Impact factor: 4.849

Review 5.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

6.  Endogenous prion protein attenuates experimentally induced colitis.

Authors:  Gary R Martin; Catherine M Keenan; Keith A Sharkey; Frank R Jirik
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

Review 7.  Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application.

Authors:  Dorit Trudler; Dorit Farfara; Dan Frenkel
Journal:  Mediators Inflamm       Date:  2010-07-25       Impact factor: 4.711

8.  An integrated pathway interaction network for the combination of four effective compounds from ShengMai preparations in the treatment of cardio-cerebral ischemic diseases.

Authors:  Fang Li; Yan-ni Lv; Yi-sha Tan; Kai Shen; Ke-feng Zhai; Hong-Lin Chen; Jun-ping Kou; Bo-yang Yu
Journal:  Acta Pharmacol Sin       Date:  2015-10-12       Impact factor: 6.150

9.  Accelerated prion disease pathogenesis in Toll-like receptor 4 signaling-mutant mice.

Authors:  Daryl S Spinner; In Soo Cho; Seung Yong Park; Jae Il Kim; Harry C Meeker; Xuemin Ye; Giuseppe Lafauci; Daniel J Kerr; Michael J Flory; Bo Sook Kim; Regina B Kascsak; Thomas Wisniewski; William R Levis; Georgia B Schuller-Levis; Richard I Carp; Eunkyue Park; Richard J Kascsak
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

Review 10.  Heterogeneity of microglial activation in the innate immune response in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.